Swedbank AB Grows Stock Position in Gilead Sciences, Inc. $GILD

Swedbank AB lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.8% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 2,505,240 shares of the biopharmaceutical company’s stock after acquiring an additional 43,205 shares during the period. Swedbank AB’s holdings in Gilead Sciences were worth $307,493,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Brighton Jones LLC boosted its stake in Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after purchasing an additional 2,450 shares in the last quarter. Bison Wealth LLC acquired a new position in Gilead Sciences during the 4th quarter valued at approximately $215,000. Sivia Capital Partners LLC increased its stake in Gilead Sciences by 16.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after purchasing an additional 602 shares in the last quarter. Ieq Capital LLC raised its holdings in shares of Gilead Sciences by 12.0% in the second quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock worth $13,160,000 after buying an additional 12,705 shares during the last quarter. Finally, Diversify Advisory Services LLC raised its holdings in shares of Gilead Sciences by 18.6% in the second quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock worth $516,000 after buying an additional 674 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Up 0.6%

GILD stock opened at $133.48 on Wednesday. The company has a market capitalization of $165.68 billion, a P/E ratio of 19.72, a price-to-earnings-growth ratio of 1.75 and a beta of 0.31. Gilead Sciences, Inc. has a 12 month low of $95.29 and a 12 month high of $157.29. The firm’s fifty day simple moving average is $140.14 and its 200-day simple moving average is $132.66. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.83 by $0.03. The firm had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm’s revenue was up 4.7% compared to the same quarter last year. During the same quarter last year, the company posted $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 8.62 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on GILD. Rothschild & Co Redburn boosted their price objective on shares of Gilead Sciences from $159.00 to $170.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Truist Financial raised their target price on Gilead Sciences from $145.00 to $152.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Leerink Partners lifted their price target on Gilead Sciences from $146.00 to $148.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 11th. Deutsche Bank Aktiengesellschaft boosted their price target on Gilead Sciences from $135.00 to $155.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. Finally, TD Cowen increased their price objective on Gilead Sciences from $145.00 to $160.00 and gave the company a “buy” rating in a report on Wednesday, February 11th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $157.35.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: AHF says Gilead’s EPS could rise ~52% because state AIDS drug program shortfalls have increased reliance on commercial/retail supply, implying near-term revenue upside for Gilead’s HIV portfolio. Gilead’s Earnings Skyrocket as Florida’s AIDS Drug Program Falters, says AHF
• Positive Sentiment: Brokerage commentary and price-target coverage are constructive — a recent note cites a $157.35 target, supporting investor expectations of upside versus current levels. Brokerages Set Gilead Sciences, Inc. (NASDAQ:GILD) Price Target at $157.35
• Neutral Sentiment: Use of Yeztugo (twice-yearly HIV-prevention shot) is rising since launch, which supports Gilead’s growth story in prevention, but adoption is still early and incremental to overall revenues. Focus: Use of Gilead’s HIV prevention shot rises, but US insurance gaps remain
• Neutral Sentiment: Analyst/estimate deep dives (Zacks/market write-ups) are circulating ahead of quarterly reporting; these pieces highlight key metrics investors will watch (sales mix of HIV products, hepatitis/oncology performance, and guidance). That keeps focus on fundamentals rather than a single headline. Curious about Gilead (GILD) Q1 Performance? Explore Wall Street Estimates for Key Metrics
• Neutral Sentiment: Brand/marketing recognition (PLAN C Impact 50) is positive for awareness but unlikely to move near-term fundamentals materially. Eight PLAN C Client Brands Named to the 3AF 2026 Impact 50
• Negative Sentiment: Insurance coverage gaps for Yeztugo remain a real constraint — patients who want the injection can face reimbursement hurdles, which could cap upside in medium-term prevention revenue if not resolved. Use of Gilead’s HIV prevention shot rises, but US insurance gaps remain

Insider Buying and Selling at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 115,640 shares of the firm’s stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $150.00, for a total transaction of $17,346,000.00. Following the sale, the chief executive officer directly owned 613,912 shares of the company’s stock, valued at $92,086,800. This trade represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total value of $422,880.00. Following the transaction, the chief financial officer owned 176,191 shares of the company’s stock, valued at approximately $24,835,883.36. This represents a 1.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 178,640 shares of company stock worth $26,584,250. Insiders own 0.30% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.